Liberation Labs Selects Indiana for First Biomanufacturing Facility
The new facility will be a purpose-built commercial precision fermentation plant
Liberation Labs, a large-scale precision fermentation manufacturer, has executed a purchase agreement for the site of its first commercial-scale biomanufacturing facility. The new facility, which will have a fermentation capacity of 600,000 liters with a fully dedicated downstream process (DSP), will be located in the Midwest Industrial Park in Richmond, Ind. Commercial production is expected by the end of 2024.
Liberation Labs is focused on enabling the commercial availability of bioproducts that will meet the growing demand from existing major CPG and ingredient brands as well as from the emerging crop of precision fermentation-focused startups. The new facility will be the first purpose-built commercial-scale precision fermentation plant in the United States. The company has completed Front End Loading level 3 engineering (FEL-3) and has begun placing orders for long-lead equipment and building out the operations team. Groundbreaking is expected later this spring.